SIRPA and neoplasm: In immune checkpoint inhibitor-based therapies, CD47-SIRPα blockers enhance tumor cell clearance through TANs-mediated trogocytosis of antibody-labeled tumor cells, while targeting FcγRIIa (CD32a) and FcαRI (CD89) optimizes antibody-dependent cellular cytotoxicity (ADCC) (103).